---
title: "Precision BioSciences, Inc. (DTIL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DTIL.US.md"
symbol: "DTIL.US"
name: "Precision BioSciences, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T11:27:03.114Z"
locales:
  - [en](https://longbridge.com/en/quote/DTIL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DTIL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DTIL.US.md)
---

# Precision BioSciences, Inc. (DTIL.US)

## Company Overview

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [recisionbiosciences.com](https://recisionbiosciences.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.63)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 266 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -11.87% |  |
| Net Profit YoY | -98.31% |  |
| P/B Ratio | 2.34 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 178035504.30 |  |
| Revenue | 45073000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -70.93% | E |
| Profit Margin | -96.73% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -11.87% | E |
| Net Profit YoY | -98.31% | E |
| Total Assets YoY | 15.66% | B |
| Net Assets YoY | 54.25% | A |
| Cash Flow Margin | 134.70% | B |
| OCF YoY | -11.87% | E |
| Turnover | 0.34 | D |
| Gearing Ratio | 47.11% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Precision BioSciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-11.87%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-98.31%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.34",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "178035504.30",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "45073000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-70.93%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-96.73%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-11.87%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-98.31%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "15.66%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "54.25%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "134.70%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-11.87%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.34",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "47.11%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.08 | 357/386 | - | - | - |
| PB | 2.34 | 213/386 | 5.98 | 2.04 | 1.48 |
| PS (TTM) | 3.95 | 90/386 | 141.40 | 46.74 | 1.12 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-06T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.90 |
| Highest Target | 60.00 |
| Lowest Target | 19.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/DTIL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/DTIL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/DTIL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/DTIL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**